PD-(L)1 monotherapy approved tumor types61 (without consideration of PD-L1 IHC status) had a substantially higher proportion of IRS-H patients (37.6%) than non-PD-(L)1 monotherapy approved tumor types (11.7%) (Fig. 5b). The gene discussed is CD274; the disease is neoplasm.